Modeling long-term health outcomes of patients with cystic fibrosis homozygous for F508del-CFTR treated with lumacaftor/ivacaftor

BACKGROUND: Lumacaftor/ivacaftor combination therapy is efficacious and generally safe for patients with cystic fibrosis (CF) homozygous for the F508del-CF transmembrane conductance regulator (CFTR) mutation. However, long-term survival benefits of lumacaftor/ivacaftor (LUM/IVA) cannot yet be quanti...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Ther Adv Respir Dis
Egile Nagusiak: Rubin, Jaime L., O’Callaghan, Lasair, Pelligra, Christopher, Konstan, Michael W., Ward, Alexandra, Ishak, Jack K., Chandler, Conor, Liou, Theodore G.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2019
Gaiak:
Original Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6366006/
https://ncbi.nlm.nih.gov/pubmed/30803355
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618820186
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak